ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 167

Target Serum Urate: Do Patients Know Their Goal?

Brian W. Coburn1, Kayli A. Bendlin2, Harlan Sayles1, Kathryn S. Hentzen3, Michaela M. Hrdy3 and Ted R. Mikuls1, 1Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 2Pharmacy, Omaha VA Medical Center, Omaha, NE, 3Omaha VA Medical Center, Omaha, NE

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: gout, knowledge and patient engagement

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Metabolic and Crystal Arthropathies: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in gout using urate lowering therapy (ULT).  However, suboptimal rates of serum urate (sUA) goal achievement and ULT dose titration in clinical data indicate that providers are not routinely adopting treat-to-target strategies in gout. According to the Chronic Care Model a viable strategy for improving outcomes may be to directly engage gout patients in their care, an approach that requires patient knowledge of sUA goals. The objective of this study was to examine knowledge of sUA goals among gout patients treated with ULT and to identify factors associated with this knowledge.

Methods:

Questionnaires were mailed to 1437 gout patients receiving an allopurinol prescription between August 1, 2011 and July 31, 2012. Of these, 886 (62%) surveys were returned. Patients were asked in a multiple choice format “What is the ideal blood uric acid level to aim for when treating gout?” In addition to sociodemographic, health, and gout-related factors, analysis included Patient Activation Measure (PAMTM) scores which quantifies an individual’s self-perceived combination of skills, knowledge and confidence necessary to become engaged in their own care (range 0 to 100).  A continuous measure, PAMTM scores are categorized into 4 levels from low activation (1) to high activation (4). Associations of factors with knowledge were examined using multivariable logistic regression.

Results:

Only 13% of patients correctly identified a sUA goal for ULT (< 6.0 mg/dl); 78% reported that they “didn't know” and 9% chose an incorrect answer (Table 1). This was despite a generally high level of knowledge about gout including its cause (87% correct), cause of acute flares (69%), classic symptoms (93%), use of allopurinol as ULT (83%) and indefinite duration of ULT (69%). Older age and PAMTM score were independently associated with knowing the target sUA. An increase of 15 points was associated with a 32% increase in the odds of knowing goal sUA.

Table 1. Association of Patient Characteristics with Knowledge of Target Serum Urate  Among Gout Patients Receiving Urate Lowering Therapy

Bivariate

Multivariable

Knew

Did not know

P

Odds Ratio (95% CI)

P

N = 886

109 (13%)

755 (87%)

Age, mean (SD)

69.6 (10.3)

72.8 (10.2)

<0.01

0.974 (0.954-0.994)

0.011

Male     

108 (99%)

744 (99%)

0.54

Non-Hispanic Caucasian *

95 (89%)

677 (91%)

0.54

Married *

63 (59%)

425 (57%)

0.64

High school graduate *

99 (93%)

661 (88%)

0.12

Body mass index

32.7 (5.1)

32.2 (6.3)

0.31

Age at first gout attack

47.4 (15.8)

50.3 (15.4)

0.07

Serum urate at diagnosis

7.3 (2.0)

7.0 (2.1)

0.16

Patient activation score (0-100 scale)

62.6 (11.5)

59.4 (11.6)

0.01

1.019 (1.001-1.037)

0.044

Confidence (0-10 scale)† , median (SD)

8.8 (2.0)

8.8 (2.4)

0.32

Values in bivariate analysis are frequency (%) or mean (±SD) except where noted. * The following variables were dichotomized for analysis: non-Hispanic Caucasian vs. other, currently married vs. not married and high school graduate vs. less than high school graduate. † Composite average confidence in 4 aspects of the treatment plan: discussion of medication, discussion of lifestyle and diet, able to summarize the plan and able to do all the tasks in the plan.

Conclusion:

In this population, we observed a lack of knowledge among ULT-treated gout patients about target sUA levels. Younger patients and those demonstrating lower activation were more likely to be deficient in knowledge of their sUA goal. Interventions to improve outcomes among gout patients may benefit from improving activation.



Disclosure:

B. W. Coburn,
None;

K. A. Bendlin,
None;

H. Sayles,
None;

K. S. Hentzen,
None;

M. M. Hrdy,
None;

T. R. Mikuls,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/target-serum-urate-do-patients-know-their-goal/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.